HO
HOWL.US Werewolf Therapeutics Inc
- Market cap
- USD 47.6M
- P/E
- -
- P/B
- 2.92x
- ROE
- -389.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HOWL.US undervalued?
Graham numberThe Graham number of Werewolf Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Werewolf Therapeutics Inc fundamental analysis
No fundamental analysis for Werewolf Therapeutics Inc yet.
Werewolf Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a…
Full company profileWerewolf Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Werewolf Therapeutics Inc annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 4.15M | 16.4M | 19.9M | 1.89M | 0.00 | - |
| Gross Profit | -463K | -777K | -735K | 16.4M | 18.2M | 71.0K | -1.63M | - |
| Operating Income | -9.94M | -22.4M | -50.1M | -56.1M | -40.5M | -73.6M | -60.7M | - |
| EBITDA | -9.85M | -14.9M | -49.9M | -55.0M | -32.5M | -64.0M | -53.9M | - |
| Net Income | -11.0M | -14.9M | -49.8M | -51.6M | -37.4M | -70.5M | -60.8M | -26.3M |
| EPS | -0.38 | -0.52 | -2.70 | -1.79 | -1.05 | -1.61 | -1.30 | -0.54 |
| Balance Sheet | ||||||||
| Total Assets | 21.7M | 96.4M | 179M | 160M | 175M | 127M | 69.4M | 42.8M |
| Total Liabilities | 11.9M | 7.18M | 26.5M | 37.9M | 63.5M | 53.5M | 44.6M | 36.0M |
| Shareholders' Equity | 9.77M | 89.2M | 153M | 122M | 111M | 73.4M | 24.8M | 6.76M |
| Cash & Short-term Investments | 17.9M | 92.6M | 158M | 129M | 134M | 111M | 58.0M | 41.9M |
| Total Debt | 3.14M | 2.54M | 15.7M | 14.7M | 51.9M | 37.1M | 9.44M | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -9.54M | -18.6M | -42.9M | -40.6M | -32.6M | -56.2M | -60.3M | -17.2M |
| Capital Expenditure | 266K | 560K | 498K | 3.61M | 769K | 254K | 0.00 | 0.00 |
| Free Cash Flow | -9.81M | -19.2M | -43.4M | -44.2M | -33.4M | -56.4M | -60.3M | -17.2M |
| Ratios | ||||||||
| ROE | -112.5% | -16.7% | -32.6% | -42.1% | -33.6% | -96.1% | -245.2% | -389.4% |
| ROA | -50.7% | -15.5% | -27.8% | -32.2% | -21.4% | -55.6% | -87.6% | -61.6% |
| Net Profit Margin | - | - | -1,199.8% | -314.4% | -187.4% | -3,740.8% | - | - |
| Debt to Equity | 0.32x | 0.03x | 0.10x | 0.12x | 0.47x | 0.51x | 0.38x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Werewolf Therapeutics Inc dividends
Werewolf Therapeutics Inc has not paid dividends in the last 7 fiscal years.
Who owns Werewolf Therapeutics Inc
- Insiders 6.63%
- Institutions 42.34%
- Public & others 51.04%
- Shares outstanding 48.6M
- Free float 45.4M
Top funds holding HOWL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 874K | 1.80% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 203K | 0.42% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 54.6K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 42.6K | 0.09% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 30.6K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 10.5K | 0.02% | 0.00% | Aug 2026 |
| Guggenheim Active Allocation Fund | 306.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding HOWL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 2.39M | 4.91% | -64.26% | Jun 2026 |
| Balyasny Asset Management LLC | 1.79M | 3.68% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.22M | 2.51% | 0.00% | Jun 2026 |
| Lynx1 Capital Management, LP | 658K | 1.35% | 0.00% | Jun 2026 |
| Sphera Funds Management Ltd. | 627K | 1.29% | 0.00% | Jun 2026 |
| DC Funds, LP | 589K | 1.21% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 551K | 1.13% | -18.34% | Sep 2026 |
| Verdad Advisers, LP | 349K | 0.72% | +1,071.74% | Jun 2026 |
| Geode Capital Management, LLC | 336K | 0.69% | -13.78% | Jun 2026 |
| Acadian Asset Management LLC | 317K | 0.65% | 0.00% | Sep 2026 |
| Bank of America Corp | 312K | 0.64% | +17.73% | Jun 2026 |
| XTX Topco Ltd | 271K | 0.56% | +433.05% | Jun 2026 |
| Jane Street Group LLC | 252K | 0.52% | +204.02% | Jun 2026 |
| UBS Group AG | 216K | 0.44% | +222.84% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 158K | 0.32% | 0.00% | Jun 2026 |
| State Street Corp | 119K | 0.25% | 0.00% | Jun 2026 |
| Squarepoint Ops LLC | 103K | 0.21% | 0.00% | Jun 2026 |
| BlackRock Inc | 102K | 0.21% | -0.03% | Jun 2026 |
| Northern Trust Corp | 86.9K | 0.18% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 86.6K | 0.18% | 0.00% | Jun 2026 |
Werewolf Therapeutics Inc company profile
- Company name
- Werewolf Therapeutics Inc
- Ticker
- HOWL.US
- Exchange
- USA Stocks
- Listed since
- Apr 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 39
- Fiscal year end
- December
- Address
- 200 Talcott Ave, Watertown, MA, United States, 02472
- Phone
- 617 952 0555
- Website
- werewolftx.com
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Werewolf Therapeutics Inc management
1- Dr. Daniel J. Hicklin Ph.D.Founder, CEO, President & Director · born 1964